Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9466 |
High Similarity |
NPD252 |
Clinical (unspecified phase) |
0.9353 |
High Similarity |
NPD3086 |
Phase 3 |
0.9281 |
High Similarity |
NPD3085 |
Phase 1 |
0.9098 |
High Similarity |
NPD194 |
Clinical (unspecified phase) |
0.9097 |
High Similarity |
NPD4074 |
Clinical (unspecified phase) |
0.9084 |
High Similarity |
NPD9632 |
Phase 3 |
0.9044 |
High Similarity |
NPD549 |
Approved |
0.8321 |
Intermediate Similarity |
NPD9607 |
Approved |
0.8311 |
Intermediate Similarity |
NPD338 |
Approved |
0.8299 |
Intermediate Similarity |
NPD283 |
Approved |
0.8255 |
Intermediate Similarity |
NPD339 |
Approved |
0.8252 |
Intermediate Similarity |
NPD582 |
Approved |
0.8244 |
Intermediate Similarity |
NPD9606 |
Approved |
0.8188 |
Intermediate Similarity |
NPD242 |
Approved |
0.812 |
Intermediate Similarity |
NPD9409 |
Discontinued |
0.8079 |
Intermediate Similarity |
NPD169 |
Phase 2 |
0.8071 |
Intermediate Similarity |
NPD209 |
Clinical (unspecified phase) |
0.8054 |
Intermediate Similarity |
NPD353 |
Discontinued |
0.8015 |
Intermediate Similarity |
NPD9374 |
Approved |
0.8013 |
Intermediate Similarity |
NPD247 |
Clinical (unspecified phase) |
0.8 |
Intermediate Similarity |
NPD545 |
Clinical (unspecified phase) |
0.791 |
Intermediate Similarity |
NPD307 |
Approved |
0.7891 |
Intermediate Similarity |
NPD250 |
Approved |
0.7891 |
Intermediate Similarity |
NPD249 |
Approved |
0.7881 |
Intermediate Similarity |
NPD536 |
Clinical (unspecified phase) |
0.7872 |
Intermediate Similarity |
NPD547 |
Clinical (unspecified phase) |
0.7863 |
Intermediate Similarity |
NPD9373 |
Approved |
0.7785 |
Intermediate Similarity |
NPD186 |
Discovery |
0.7785 |
Intermediate Similarity |
NPD195 |
Approved |
0.7744 |
Intermediate Similarity |
NPD4716 |
Approved |
0.7697 |
Intermediate Similarity |
NPD4744 |
Clinical (unspecified phase) |
0.7597 |
Intermediate Similarity |
NPD1369 |
Phase 2 |
0.7597 |
Intermediate Similarity |
NPD1750 |
Clinical (unspecified phase) |
0.7568 |
Intermediate Similarity |
NPD1431 |
Approved |
0.7568 |
Intermediate Similarity |
NPD1430 |
Approved |
0.7564 |
Intermediate Similarity |
NPD219 |
Phase 3 |
0.7564 |
Intermediate Similarity |
NPD216 |
Approved |
0.7564 |
Intermediate Similarity |
NPD220 |
Clinical (unspecified phase) |
0.7564 |
Intermediate Similarity |
NPD218 |
Approved |
0.7564 |
Intermediate Similarity |
NPD217 |
Approved |
0.7564 |
Intermediate Similarity |
NPD2624 |
Phase 2 |
0.7517 |
Intermediate Similarity |
NPD185 |
Approved |
0.75 |
Intermediate Similarity |
NPD775 |
Approved |
0.7484 |
Intermediate Similarity |
NPD3107 |
Discontinued |
0.7455 |
Intermediate Similarity |
NPD4171 |
Clinical (unspecified phase) |
0.7453 |
Intermediate Similarity |
NPD7988 |
Suspended |
0.7452 |
Intermediate Similarity |
NPD1732 |
Phase 3 |
0.7452 |
Intermediate Similarity |
NPD2646 |
Discontinued |
0.7417 |
Intermediate Similarity |
NPD166 |
Approved |
0.741 |
Intermediate Similarity |
NPD1412 |
Clinical (unspecified phase) |
0.7388 |
Intermediate Similarity |
NPD9375 |
Discontinued |
0.7383 |
Intermediate Similarity |
NPD193 |
Suspended |
0.7372 |
Intermediate Similarity |
NPD214 |
Approved |
0.7372 |
Intermediate Similarity |
NPD213 |
Clinical (unspecified phase) |
0.7365 |
Intermediate Similarity |
NPD1808 |
Phase 1 |
0.7267 |
Intermediate Similarity |
NPD3083 |
Approved |
0.723 |
Intermediate Similarity |
NPD1121 |
Approved |
0.723 |
Intermediate Similarity |
NPD1120 |
Approved |
0.7209 |
Intermediate Similarity |
NPD6417 |
Clinical (unspecified phase) |
0.7153 |
Intermediate Similarity |
NPD515 |
Phase 1 |
0.7126 |
Intermediate Similarity |
NPD2632 |
Approved |
0.7126 |
Intermediate Similarity |
NPD2631 |
Clinical (unspecified phase) |
0.7126 |
Intermediate Similarity |
NPD2630 |
Approved |
0.7115 |
Intermediate Similarity |
NPD548 |
Clinical (unspecified phase) |
0.7089 |
Intermediate Similarity |
NPD9605 |
Phase 3 |
0.6989 |
Remote Similarity |
NPD4054 |
Clinical (unspecified phase) |
0.6988 |
Remote Similarity |
NPD2647 |
Phase 3 |
0.6978 |
Remote Similarity |
NPD9584 |
Phase 2 |
0.695 |
Remote Similarity |
NPD9360 |
Approved |
0.6918 |
Remote Similarity |
NPD7842 |
Phase 2 |
0.6882 |
Remote Similarity |
NPD5666 |
Phase 2 |
0.6831 |
Remote Similarity |
NPD237 |
Clinical (unspecified phase) |
0.6815 |
Remote Similarity |
NPD9626 |
Clinical (unspecified phase) |
0.68 |
Remote Similarity |
NPD1692 |
Approved |
0.6741 |
Remote Similarity |
NPD8837 |
Clinical (unspecified phase) |
0.6712 |
Remote Similarity |
NPD798 |
Discontinued |
0.6707 |
Remote Similarity |
NPD546 |
Clinical (unspecified phase) |
0.6684 |
Remote Similarity |
NPD6381 |
Phase 2 |
0.6667 |
Remote Similarity |
NPD248 |
Discontinued |
0.6648 |
Remote Similarity |
NPD2152 |
Clinical (unspecified phase) |
0.6646 |
Remote Similarity |
NPD7158 |
Phase 1 |
0.6642 |
Remote Similarity |
NPD9291 |
Approved |
0.6627 |
Remote Similarity |
NPD1777 |
Approved |
0.6627 |
Remote Similarity |
NPD1776 |
Approved |
0.66 |
Remote Similarity |
NPD9633 |
Phase 3 |
0.6594 |
Remote Similarity |
NPD1816 |
Clinical (unspecified phase) |
0.6587 |
Remote Similarity |
NPD516 |
Clinical (unspecified phase) |
0.6536 |
Remote Similarity |
NPD5683 |
Clinical (unspecified phase) |
0.6536 |
Remote Similarity |
NPD5682 |
Phase 3 |
0.6536 |
Remote Similarity |
NPD5684 |
Clinical (unspecified phase) |
0.6533 |
Remote Similarity |
NPD870 |
Clinical (unspecified phase) |
0.651 |
Remote Similarity |
NPD9408 |
Phase 3 |
0.6482 |
Remote Similarity |
NPD6036 |
Suspended |
0.6429 |
Remote Similarity |
NPD9416 |
Phase 3 |
0.6429 |
Remote Similarity |
NPD9417 |
Phase 3 |
0.6409 |
Remote Similarity |
NPD7138 |
Phase 2 |
0.6301 |
Remote Similarity |
NPD1368 |
Approved |
0.6289 |
Remote Similarity |
NPD3695 |
Approved |
0.6289 |
Remote Similarity |
NPD3696 |
Approved |
0.6264 |
Remote Similarity |
NPD1063 |
Phase 2 |
0.6218 |
Remote Similarity |
NPD5340 |
Clinical (unspecified phase) |
0.6194 |
Remote Similarity |
NPD282 |
Approved |
0.6178 |
Remote Similarity |
NPD1119 |
Phase 2 |
0.6145 |
Remote Similarity |
NPD3708 |
Phase 2 |
0.6104 |
Remote Similarity |
NPD1356 |
Approved |
0.6104 |
Remote Similarity |
NPD1354 |
Approved |
0.6104 |
Remote Similarity |
NPD1355 |
Clinical (unspecified phase) |
0.609 |
Remote Similarity |
NPD9650 |
Phase 3 |
0.6078 |
Remote Similarity |
NPD4812 |
Phase 1 |
0.607 |
Remote Similarity |
NPD5080 |
Phase 2 |
0.6069 |
Remote Similarity |
NPD5768 |
Phase 2 |
0.6061 |
Remote Similarity |
NPD7531 |
Clinical (unspecified phase) |
0.6054 |
Remote Similarity |
NPD9406 |
Approved |
0.6051 |
Remote Similarity |
NPD2877 |
Clinical (unspecified phase) |
0.6051 |
Remote Similarity |
NPD2876 |
Phase 3 |
0.6049 |
Remote Similarity |
NPD2253 |
Discontinued |
0.6037 |
Remote Similarity |
NPD171 |
Discontinued |
0.602 |
Remote Similarity |
NPD5079 |
Phase 2 |
0.6 |
Remote Similarity |
NPD2965 |
Clinical (unspecified phase) |
0.5991 |
Remote Similarity |
NPD7486 |
Phase 1 |
0.599 |
Remote Similarity |
NPD2824 |
Phase 2 |
0.599 |
Remote Similarity |
NPD5665 |
Clinical (unspecified phase) |
0.5976 |
Remote Similarity |
NPD231 |
Clinical (unspecified phase) |
0.5976 |
Remote Similarity |
NPD4240 |
Approved |
0.5943 |
Remote Similarity |
NPD6840 |
Approved |
0.5934 |
Remote Similarity |
NPD1046 |
Clinical (unspecified phase) |
0.593 |
Remote Similarity |
NPD3697 |
Discontinued |
0.5897 |
Remote Similarity |
NPD1127 |
Approved |
0.5897 |
Remote Similarity |
NPD1128 |
Approved |
0.589 |
Remote Similarity |
NPD1118 |
Discontinued |
0.5871 |
Remote Similarity |
NPD281 |
Approved |
0.5838 |
Remote Similarity |
NPD2604 |
Approved |
0.5818 |
Remote Similarity |
NPD1117 |
Clinical (unspecified phase) |
0.58 |
Remote Similarity |
NPD3139 |
Phase 3 |
0.5756 |
Remote Similarity |
NPD1731 |
Clinical (unspecified phase) |
0.5745 |
Remote Similarity |
NPD1454 |
Phase 3 |
0.5745 |
Remote Similarity |
NPD1455 |
Phase 3 |
0.5741 |
Remote Similarity |
NPD535 |
Approved |
0.5733 |
Remote Similarity |
NPD3138 |
Phase 3 |
0.5723 |
Remote Similarity |
NPD2180 |
Approved |
0.5714 |
Remote Similarity |
NPD284 |
Phase 1 |
0.5714 |
Remote Similarity |
NPD1730 |
Discontinued |
0.5714 |
Remote Similarity |
NPD2902 |
Phase 2 |
0.5714 |
Remote Similarity |
NPD2903 |
Clinical (unspecified phase) |
0.5714 |
Remote Similarity |
NPD4599 |
Clinical (unspecified phase) |
0.5693 |
Remote Similarity |
NPD4495 |
Phase 1 |
0.5625 |
Remote Similarity |
NPD8829 |
Clinical (unspecified phase) |
0.5625 |
Remote Similarity |
NPD1061 |
Clinical (unspecified phase) |
0.5621 |
Remote Similarity |
NPD578 |
Discontinued |
0.5617 |
Remote Similarity |
NPD9083 |
Clinical (unspecified phase) |
0.5616 |
Remote Similarity |
NPD9415 |
Clinical (unspecified phase) |
0.5605
|
Remote Similarity |
NPD9084 |
Phase 2 |